NO20054714D0 - Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom - Google Patents

Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom

Info

Publication number
NO20054714D0
NO20054714D0 NO20054714A NO20054714A NO20054714D0 NO 20054714 D0 NO20054714 D0 NO 20054714D0 NO 20054714 A NO20054714 A NO 20054714A NO 20054714 A NO20054714 A NO 20054714A NO 20054714 D0 NO20054714 D0 NO 20054714D0
Authority
NO
Norway
Prior art keywords
procedures
disease
preventing
cognitive impairments
treating weak
Prior art date
Application number
NO20054714A
Other languages
English (en)
Other versions
NO20054714L (no
Inventor
Mark Steven Shearman
Mervyn Turner
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20054714D0 publication Critical patent/NO20054714D0/no
Publication of NO20054714L publication Critical patent/NO20054714L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20054714A 2003-03-14 2005-10-13 Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom NO20054714L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45458903P 2003-03-14 2003-03-14
PCT/GB2004/000983 WO2004080459A1 (en) 2003-03-14 2004-03-08 Method for treating mild cognitive impairment and for preventing or delaying alzheimer’s disease

Publications (2)

Publication Number Publication Date
NO20054714D0 true NO20054714D0 (no) 2005-10-13
NO20054714L NO20054714L (no) 2005-11-16

Family

ID=32990914

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054714A NO20054714L (no) 2003-03-14 2005-10-13 Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom

Country Status (13)

Country Link
US (1) US20060241133A1 (no)
EP (1) EP1605940A1 (no)
JP (1) JP2006520371A (no)
KR (1) KR20050109990A (no)
CN (1) CN1794992A (no)
AU (1) AU2004218871A1 (no)
BR (1) BRPI0408295A (no)
CA (1) CA2518886A1 (no)
IS (1) IS8004A (no)
MX (1) MXPA05009850A (no)
NO (1) NO20054714L (no)
RU (1) RU2005131845A (no)
WO (1) WO2004080459A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313772D0 (en) * 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
WO2007061670A1 (en) 2005-11-21 2007-05-31 Amgen Inc. Beta-secretase modulators and methods of use
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
MX2009012608A (es) 2007-05-25 2009-12-07 Amgen Inc Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso.
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
MY148558A (en) * 2008-09-11 2013-04-30 Amgen Inc Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
WO2011063272A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
AU2011207679B2 (en) 2010-01-19 2013-10-10 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CA2791281A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators
EP2547686B1 (en) 2010-03-15 2014-01-22 Amgen Inc. Amino-dihydrooxazine and amino-dihydrothiazine spiro compounds as beta-secretase modulators and their medical use
EP2673279A1 (en) 2011-02-07 2013-12-18 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
LU92126B1 (fr) * 2012-12-31 2014-07-01 Cesa Alliance Sa Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902680A (en) * 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
PL176993B1 (pl) * 1992-12-11 1999-08-31 Merck & Co Inc Nowe związki spiropiperydynowe oraz sposób ich wytwarzania
WO1996033189A1 (en) * 1995-04-19 1996-10-24 Merck & Co., Inc. Process for the preparation of spiroindolines
US5767124A (en) * 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
US6028196A (en) * 1995-10-27 2000-02-22 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
EP0900086A4 (en) * 1996-05-07 2000-01-12 Merck & Co Inc IMPROVING THE SLEEP BY MEANS OF A SUBSTANCE PROMOTING THE SECRETION OF GROWTH HORMONES
US6046333A (en) * 1996-10-25 2000-04-04 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
WO2000013650A2 (en) * 1998-09-03 2000-03-16 Neuronz Limited Neuroprotection
ATE304373T1 (de) * 1999-12-28 2005-09-15 Kaken Pharma Co Ltd Nervenschutzmittel
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues

Also Published As

Publication number Publication date
MXPA05009850A (es) 2005-12-06
WO2004080459A1 (en) 2004-09-23
AU2004218871A1 (en) 2004-09-23
IS8004A (is) 2005-08-29
KR20050109990A (ko) 2005-11-22
CA2518886A1 (en) 2004-09-23
JP2006520371A (ja) 2006-09-07
NO20054714L (no) 2005-11-16
BRPI0408295A (pt) 2006-03-07
RU2005131845A (ru) 2006-02-10
EP1605940A1 (en) 2005-12-21
US20060241133A1 (en) 2006-10-26
CN1794992A (zh) 2006-06-28

Similar Documents

Publication Publication Date Title
NO20054714D0 (no) Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom
DK1303272T3 (da) Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom
EP1765388B8 (de) Kombinationstherapie zur vorbeugung oder behandlung der alzheimerschen erkrankung sowie set hierfür
AU2003220096A1 (en) Methods for alzheimer's disease treatment and cognitive enhancement
IL234291A (en) Ribstigmine for use in the prevention, treatment or delay of the progression of dementia or Alzheimer's disease
DK1224297T3 (da) Alzheimers sygdom -sekretase, APP-substrater derfor og anvendelser deraf
NO20050427L (no) Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmater
DK2527315T3 (da) Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom
DK1613296T3 (da) Fremgangsmåder til behandling af Parkinsons sygdom
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
NO20035609L (no) Fremgangsmate for kontinuerlig naftabehandling
EP1535971A4 (en) TREATED PIGMENT, ITS USE, AND COMPOUND FOR THE TREATMENT OF PIGMENTS
DK2211183T3 (da) Fremgangsmåde til diagnosticering og overvågning af Alzheimer's sygdom
DK1443955T3 (da) PDGF-BB til behandling af Parkinsons sygdom
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
DK2026819T3 (da) Forebyggelse og/eller behandling af Alzheimers sygdom
WO2006110588A3 (en) Methods for treating mild cognitive impairment
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
DK1202996T3 (da) Titanforbindelser, fremstilling og anvendelse heraf
AU2003256789A8 (en) Method of detecting and preventing alzheimer's disease, particularly at prodromal and early stages
AU2003221211A1 (en) Coumarins extractions and their uses for treating hypertension disease
AU2002329784A1 (en) Molecules for disease detection and treatment
AU2003205174A1 (en) Molecules for disease detection and treatment
AU2002347899A1 (en) Molecules for disease detection and treatment